Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2019-08-28 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019'. It contains comprehensive financial summaries, including net turnover, EBITDA, earnings per share, and cash flow for the specified period. It also includes a detailed CEO's message, project portfolio updates, and clinical trial results. As it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H2 2019
2019-08-28 English
Selective effect signal on liver cancer tissue in phase Ia study with MIV-818
Earnings Release Classification · 92% confidence The document is a press release from Medivir AB announcing preliminary results from a Phase Ia clinical study for their drug MIV-818, specifically noting positive early efficacy signals (DNA damage in tumor tissue) and the decision to proceed to Phase Ib. It includes quotes from the CEO, details about an upcoming conference call for investors/media, and standard 'About' sections. This format—an immediate announcement of key clinical/business developments, often preceding a formal financial report—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is focused on announcing specific study results and the next steps, it fits best under 'Earnings Release' (ER) as it communicates key performance/development milestones to the market, even if it's not strictly quarterly financial results. It is too detailed to be a simple RPA, and it is not a full financial report (10-K/IR) or a transcript (CT). Given the context of reporting clinical trial progress which drives investor sentiment, ER is the most appropriate fit among the choices, although RNS is a close secondary fallback. FY 2019
2019-06-13 English
Selektiv effektsignal i levercancervävnad i fas Ia-studien med MIV-818
Regulatory Filings Classification · 94% confidence The document is a press release from Medivir AB announcing preliminary results from a Phase Ia clinical trial for their drug MIV-818 in liver cancer patients. It details safety, efficacy signals (DNA damage in tumor tissue), and the decision to proceed to Phase Ib. Crucially, it announces an upcoming conference call for investors and media to discuss these initial results, stating that the presentation will be available on the website afterward. Since the document itself is an announcement of results and an upcoming presentation/call, and it is relatively short (under 5,000 characters), it fits the criteria for a Report Publication Announcement (RPA) or potentially an Earnings Release (ER) if it were quarterly results. However, this is a clinical trial update, not a standard financial earnings report. The text explicitly mentions the conference call and that the presentation will follow. Given the context of announcing clinical progress and scheduling a follow-up event, it is best classified as a general announcement related to company progress, which often falls under Regulatory Filings (RNS) if no other specific category fits perfectly. However, since it is announcing the *release* of information (the results) and scheduling a call to discuss it, RPA is a strong candidate, but RNS is the most appropriate fallback for non-standard regulatory/corporate updates that aren't financial results (ER) or management changes (MANG). Since it is a specific update on a drug trial, and not a formal financial report, RNS is the safest general classification for a non-standard corporate announcement.
2019-06-13 Swedish
Beslut vid årsstämma i Medivir den 9 maj 2019
AGM Information Classification · 99% confidence The document title explicitly states "Beslut vid årsstämma i Medivir den 9 maj 2019" (Decisions at the Annual General Meeting in Medivir on May 9, 2019). The content details resolutions passed regarding the approval of financial statements, discharge of management, dividend disposition, remuneration for the board and auditor, election of the board and auditor, and decisions on the nomination committee process and executive compensation guidelines. These are all core topics discussed and resolved at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length (3814 chars) is substantial enough to be the actual minutes/summary of decisions, not just a brief announcement of an upcoming meeting.
2019-05-09 Swedish
Resolutions at the Annual General Meeting in Medivir on 9 May 2019
AGM Information Classification · 99% confidence The document explicitly details the resolutions passed during the 'Annual General Meeting in Medivir on 9 May 2019'. It covers the approval of financial statements, discharge from liability, remuneration decisions, election of the board and auditor, and authorization for new share issues, all of which are standard agenda items and outcomes of an AGM. This directly corresponds to the definition of 'AGM Information' (Code: AGM-R). Although it mentions financial results approval, the primary focus and structure are the meeting outcomes, not the full financial report (10-K or IR) or a simple announcement of the meeting (DEF 14A or PSI).
2019-05-09 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB for the period January-March 2019. It contains comprehensive financial statements, management commentary, and operational updates for the quarter. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, thus fitting the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-03 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.